フルテキストファイル
著者
Kubouchi Yasuaki Division of General Thoracic Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine
Kidokoro Yoshiteru Division of General Thoracic Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine 鳥取大学研究者総覧
Ohno Takashi Division of General Thoracic Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine
Yurugi Yohei Division of General Thoracic Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine
Wakahara Makoto Division of General Thoracic Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine 鳥取大学研究者総覧
Haruki Tomohiro Division of General Thoracic Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine 鳥取大学研究者総覧 KAKEN研究者をさがす
Nakamura Hiroshige Division of General Thoracic Surgery, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine 鳥取大学研究者総覧 KAKEN研究者をさがす
キーワード
epidermal growth factor receptor tyrosine kinase inhibitors
non-small cell lung cancer
post recurrecurrence
prognostic factor
NDC分類
4類 自然科学
抄録
[Background]Recurrence of lung cancer after surgical resection is a major obstacle in the cure and long-term survival of patients and has become the most common cause of death. However, prognostic factors and efficacy of therapy after recurrence remain controversial. We evaluated the prognostic factors of post recurrence survival (PRS) in patients of resected stage I non-small cell lung cancer (NSCLC).
[Methods]Of the 551 patients who underwent surgery for stage I NSCLC between 2005 and 2013, we reviewed 89 (16.2%) patients who had recurrence. We examined PRS using the Kaplan–Meier method and multivariate Cox regression analyses.
[Results]The median follow-up period after recurrence was 21.0 months. The median recurrence free interval (RFI) was 16.8 months. The 1-year PRS and 3-year PRS were 65.6% and 44.7%, respectively. Multivariate analysis revealed that size of primary lesion > 25 mm (P = 0.048), RFI ≤ 17 months (P = 0.048) and no treatment for recurrence (P < 0.001) were independent poor-prognosis factors of PRS. We further examined PRS in 66 patients who underwent any post recurrence therapy. For the patients who underwent treatment after recurrence, bone metastasis (P = 0.025) and treatment without epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) (P = 0.049) were independent poor prognostic factors.
[Conclusion]PRS may be associated with characteristics of a recurrent lesion, including the biology of the recurrent tumor, RFI, recurrent site, the treatment for recurrence, rather than characteristics of primary lesion. Although further validation is needed, this information is important for the design of clinical trials for post-recurrence therapy.
出版者
Tottori University Faculty of Medicine
資料タイプ
学術雑誌論文
ISSN・ISBN
1346-8049
書誌ID
AA00892882
掲載誌名
Yonago Acta Medica
最新掲載誌名
Yonago Acta Medica
60
4
開始ページ
213
終了ページ
219
発行日
2018-02-05
著者版フラグ
出版社版
掲載情報
Yonago Acta Medica. 2017,60(4),213–219
部局名
医学部・医学系研究科・医学部附属病院
言語
英語